The Economist's War On Cancer Forum
September 29th | Boston
healthcare.economist.com

Pharma's current role in the cancer ecosystem

Approximately $91 billion was spent on cancer drugs last year, and yet it takes 10 to 15 years and up to $1.2 billion to bring a new cancer drug to market. Are big pharma companies the best home for drug development?<br /><br />
Attend The Economist Events' War on Cancer conference on September 29th to explore how to close the gaps that remain in the FDA drug-approval process and find ways for further collaboration between research and development.<br /><br />

Gain perspective from senior thought leaders and contribute to the important discussions most pertinent to the pharmaceutical industry today, including:<br />
- Money misspent?: Improving cancer research for new therapies and diagnostics<br />
- Billion-dollar roulette: Can investment in drug discovery become more efficient?<br />
- The outcomes game: Synthesising approaches to cancer diagnostics and therapies<br /><br />

FEATURED SPEAKERS:<br />
- John Lin, MD, Senior vice-president, chief scientific officer, Pfizer Worldwide Research & Development<br />
- Jennifer Malin, Vice-president, clinical strategy, Anthem<br />
- Bahija Jallal, Executive vice-president, AstraZeneca and director, MedImmune<br />
- Martha Donoghue, Clinical reviewer, hematology and oncology products, US Food and Drug Administration<br /><br />

Save 10% when you register by September 8th.<br />
Enter code PE10 here: <a href="http://econ.st/1KXOCMS" target="_blank">http://econ.st/1KXOCMS</a><br /><br />

Platinum sponsor<br />
Merck<br /><br />

Gold sponsor<br />
UPS<br /><br />

Click here if you do not wish to receive any further e-mails about this event: <a href="http://response.economistevents.com/EM2202-unsubscribe" target="_blank">http://response.economistevents.com/EM2202-unsubscribe</a> The Economist Group 750 3rd Avenue, New York, NY 10017